Comparative Efficacy of Topical Therapy with a Slow-Release Mucoadhesive Buccal Tablet Containing Miconazole Nitrate Versus Systemic Therapy with Ketoconazole in HIV-Positive Patients with Oropharyngeal Candidiasis

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 2, 2004, Pages 144-150

  Van Roey, Jens ^a,c   Haxaire, Myriam ^a   Kamya, Moses ^b   Lwanga, Isaac ^b   Katabira, Elly ^b  

^a TIBOTEC BVBA   (Belgium)

^b MAKERERE UNIVERSITY   (Uganda)

^c NONE   (Belgium)

Author keywords

Miconazole nitrate; Mucoadhesive tablet; Oropharyngeal candidiasis

Indexed keywords

AMPHOTERICIN B; CLOTRIMAZOLE; FLUCONAZOLE; KETOCONAZOLE; MICONAZOLE; MICONAZOLE NITRATE; NYSTATIN;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLOW RELEASE FORMULATION; STATISTICAL ANALYSIS; TABLET; THORAX PAIN; THRUSH; TOPICAL TREATMENT; VAGINA CANDIDIASIS; VOMITING;

ADMINISTRATION, TOPICAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDIASIS; DELAYED-ACTION PREPARATIONS; FEMALE; HIV SEROPOSITIVITY; HUMANS; KETOCONAZOLE; MALE; MICONAZOLE; TABLETS;

EID: 1642499252     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200402010-00007     Document Type: Article

References (26)

1. UNAIDS. Report on the Global HIV/AIDS Epidemic. Geneva, UNAIDS; 2002.
2. Hunter KD, Gibson J, Lockhart P, et al. Fluconazole-resistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:558-564.
3. Diz Dios PD, Alvarez Alvarez J, Fernadéz Feijoo J, et al. Fluconazole response patterns in HIV-infected patients with oropharyngeal candidiasis. Oral Surg Oral Med Oral Path Oral Radiol Endod. 1995;79:170-174.
4. Greenspan D. Treatment of oropharyngeal candidiasis in HIV-positive patients. J Am Acad Dermatol. 1994;31(Suppl):S51-S55.
5. Powderly W-G, Gallant J-E, Ghannoum M-A, et al. Oropharyngeal candidiasis in patients with HIV: Suggested guidelines for therapy. AIDS Res Hum Retroviruses. 1999;15:1619-1623
6. Silverman S, Gallo JW, McKnight ML, et al. Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82:402-407.
7. MacPhail LA, Hilton JF, Dodd L, et al. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr Human Retrovirol. 1996;12:470-476.
8. Hoepelman IM, Dupont B. Oral candidiasis: the clinical challenge of resistance and management. Int J Antimicrob Agents. 1996;6:155-159.
9. Colebunders R, Mann JM, Francis H, et al. Evaluation of a clinical case definition of AIDS in Africa. Lancet. 1987;1:492-494.
10. Sonnet J, Taelman H. Clinical and biological profile of African AIDS. In: Stacquet M, Hemmer R, Baert A, eds. Clinical Aspects of AIDS and AIDS Related Complex. Oxford: Oxford University Press; 1986:78-89.
11. Global Programme on AIDS. Guidelines for the Clinical Management of HIV Infection in Adults. Geneva: WHO; 1991. Order number 1930036.
12. Nyst MJ, Perriens JH, Lusakamunu K, et al. Gentian violet, ketoconazole and nystatin in oropharyngeal and oesophageal candidiasis in Zairian AIDS patients. Ann Soc Belge Méd Trop. 1992;72:45-52.
13. Odds FC. Persistence of miconazole in saliva after a single oral dose. J Clin. Res. Rev. 1981;1:231-232.
14. Turner A, Warnock DW. Determination of miconazole in human saliva using high-performance liquid chromatography. J Chrom. 1982;227:229-232.
15. Bouckaert S, Schauttee H, Lefebvre RA, et al. Comparison of salivary miconazole concentrations after administration of a bioadhesive slow-release buccal tablet and an oral gel. Eur J Clin Pharmacol. 1992;43:137-140.
16. Janssen P, Symoens J. Hepatic reactions during ketoconazole treatment. Am J Med. 1983;74:80-85.
17. Blackwelder WC. Proving the null hypothesis in clinical trials. Control Clin Trials. 1982;3:345-353.
18. Vazquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy. 1999;19:76-87.
19. Powderly WG, Mayer KH, Perfect JR, et al. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses. 1999;15:1405-1412.
20. Odynophagia and Dysphagia. In: Clinical AIDS Care Guidelines for Resource-Poor Settings. 1st ed. Belgium-Luxemburg: Médecins Sans Frontières; 2001:11.6.
21. Van Weissenbruch R, Bouckaert S, Remon JP. Chemoprophylaxis of fungal deterioration of the Provox silicone tracheoesophageal prosthesis in postlaryngectomy patients. Ann Otol Rhinol Laryngol. 1997;106:329-337.
22. Phillips P, De Beule K, Frechette G, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis. 1998;26:1368-1373.
23. Diz Dios P, Ocampo A, Miralles C, et al. Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87:437-441.
24. Kaplan JP, Gayle HD, Castro KG. Prevention and treatment of tuberculosis among patients infected with HIV. Principles of therapy and revised recommendation. MMWR. 1998;47:34.
25. Harries AD, Hargreaves NJ, Kemp J, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet. 2001;357:1519-1523.
26. STOP TB News. The Newsletter of the Global Partnership to Stop TB. 2001;4:1-12. Availale at: www.stoptb.org.